Redesigned Scorpion Venom Peptides Kill Drug-Resistant Acinetobacter With Less Toxicity
Modified analogs of scorpion peptide Hp1404 showed improved antibacterial activity against multidrug-resistant Acinetobacter baumannii and reduced cytotoxicity, killing bacteria by disrupting both outer and inner membranes and inhibiting biofilm formation.
Quick Facts
What This Study Found
Hp1404 analog peptides showed reduced cytotoxicity, enhanced activity against MDR A. baumannii, dual membrane disruption (outer + cytoplasmic), and improved biofilm inhibition at low concentrations compared to parent peptide.
Key Numbers
14 C-terminal residues modified; active against MDR A. baumannii; membrane permeabilization (NPN, DiSC3-5); biofilm inhibition; lower cytotoxicity
How They Did This
In vitro study. Amino acid substitution at 14 C-terminal positions of scorpion peptide Hp1404. Antimicrobial testing against gram-positive and gram-negative bacteria. Cytotoxicity assessment. Membrane permeabilization (NPN uptake, DiSC3-5). Biofilm inhibition assays.
Why This Research Matters
MDR A. baumannii is classified as a critical priority pathogen by WHO. Peptides that kill it through membrane disruption and biofilm prevention address an urgent unmet medical need where traditional antibiotics are failing.
The Bigger Picture
This study demonstrates how nature's antimicrobial peptides can be rationally redesigned for clinical use — reducing toxicity while maintaining or improving antibacterial potency. The approach could be applied to other venom-derived peptides.
What This Study Doesn't Tell Us
In vitro testing only. No animal infection model data. Peptide stability in biological fluids not assessed. Manufacturing scalability and cost not addressed.
Questions This Raises
- ?Would these analog peptides be effective in vivo against A. baumannii wound or lung infections?
- ?Can the peptides be further optimized for systemic or topical delivery?
- ?Would bacteria develop resistance to these membrane-disrupting peptides over time?
Trust & Context
- Key Stat:
- Active against WHO critical pathogen Modified scorpion peptides kill multidrug-resistant A. baumannii — classified as the #1 critical priority pathogen by WHO — with reduced human cell toxicity
- Evidence Grade:
- Low evidence grade: in vitro antimicrobial testing only. Promising activity data but no animal or clinical studies.
- Study Age:
- Published 2021. Antimicrobial peptide optimization for drug-resistant bacteria continues as a high-priority research area.
- Original Title:
- Comparative Antimicrobial Activity of Hp404 Peptide and Its Analogs against Acinetobacter baumannii.
- Published In:
- International journal of molecular sciences, 22(11) (2021)
- Authors:
- Hong, Min Ji, Kim, Min Kyung, Park, Yoonkyung(2)
- Database ID:
- RPEP-05449
Evidence Hierarchy
Frequently Asked Questions
What is Acinetobacter baumannii and why is it so dangerous?
A. baumannii is a superbug commonly found in hospitals that has developed resistance to nearly all available antibiotics. It causes pneumonia, bloodstream infections, and wound infections, particularly in ICU patients. The WHO ranks it as the #1 critical priority pathogen needing new antibiotics.
How do these peptides avoid the toxicity problem?
The original scorpion peptide was effective but damaged human cells too. By strategically changing specific amino acids, researchers reduced the peptide's attraction to human cell membranes while maintaining its ability to disrupt bacterial membranes — essentially making it more selective for bacteria.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05449APA
Hong, Min Ji; Kim, Min Kyung; Park, Yoonkyung. (2021). Comparative Antimicrobial Activity of Hp404 Peptide and Its Analogs against Acinetobacter baumannii.. International journal of molecular sciences, 22(11). https://doi.org/10.3390/ijms22115540
MLA
Hong, Min Ji, et al. "Comparative Antimicrobial Activity of Hp404 Peptide and Its Analogs against Acinetobacter baumannii.." International journal of molecular sciences, 2021. https://doi.org/10.3390/ijms22115540
RethinkPeptides
RethinkPeptides Research Database. "Comparative Antimicrobial Activity of Hp404 Peptide and Its ..." RPEP-05449. Retrieved from https://rethinkpeptides.com/research/hong-2021-comparative-antimicrobial-activity-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.